Recall Register

Drug recall: Duloxetine Delayed-release Capsules USP, 20 mg, 50 Capsules (5 x 10) Unit Dose per carton, unit dose blister UPC…

Class II FDA enforcement event 78240. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Failed Impurities/Degradation Specifications: slightly elevated levels of phthalic acid.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

AVKARE Inc. started this drug recall on 6 Oct 2017. The firm address in the FDA record is in Pulaski, TN. FDA put the recall in Class II. FDA event 78240 has 1 product record. The first FDA enforcement report date is 8 Nov 2017. The record gives the status Terminated, with the termination date 11 Mar 2019.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the USA

Recalling firm

AVKARE Inc., Pulaski, TN.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 78240: product records
Recall numberProductQuantityClassStatusReport date
D-0055-2018Duloxetine Delayed-release Capsules USP, 20 mg, 50 Capsules (5 x 10) Unit Dose per carton, unit dose blister UPC 5026828311), Rx only, Manufactured for: AvKARE, Inc., Pulaski, TN 38478, NDC 50268-283-15.274 cartonsClass IITerminated8 Nov 2017

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2017
343
Share of these events in Class II
57%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
22

Other events of the firm

Other FDA enforcement events of AVKARE Inc.
InitiatedProduct (first record)TypeClassRecords
20 Jul 2022Lamotrigine Tablets, USP 100 mg, 1000-count bottles, Rx Only, Manufactured for: AvKARE, Inc. Pulaski, TN 38478, NDC 4229DrugClass III1
9 Jun 2021Phytonadione Tablets 5 mg, Rx Only, 30 Tablets (3x10) Unit Dose, Manufactured for: AvKARE Pulaski, TN 38478. NDC 50268-6DrugClass III1
7 Dec 2020Sildenafil Tablets USP 100 mg, Rx Only, 100-count Bottle, Manufactured for: AvKARE Pulaski, TN 38478, NDC 42291-748-01.DrugClass I2
30 Oct 2020Mesalamine Delayed-Release Tablets, USP 1.2 gram (Once-Daily), 120 Tablets bottle, Rx Only Manufactured for: AvKARE, IncDrugClass II1
4 Jun 2020Metformin Hydrochloride Extended-Release Tablets, USP 750 mg a) 90 count (NDC 42291-611-90) b) 180 count (NDC 42291-611-DrugClass II2
28 May 2020Lamotrigine Tablets, USP, 150 mg, Rx Only, a) 60 count Bottle, NDC 42291-368-60, b) 500 count Bottle, NDC 42291-368-50, DrugClass III1
7 Jan 2020Dutasteride Capsules, 0.5 mg, 30 Capsules (6 X 5) Unit Dose per carton, Rx Only, Manufactured for: AvKARE, Inc., PulaskiDrugClass II1
14 Nov 2019AVKARE Ranitidine Tablets, USP 150 mg Rx Only Manufactured for: AvKARE, Inc. Pulaski, TN 38478 Manufactured by: Amneal PDrugClass II2
17 Oct 2019AVKARE Ranitidine Hydrochloride Capsules 150 mg 500 Capsules Rx Only NDC 42291-735-50 UPC 342291735507 Manufactured for:DrugClass II2
28 Aug 2019AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.DrugClass II1

AVKARE Inc.: all 22 events

Official channels

Cite this page

Recall Register. FDA enforcement event 78240. https://recallregister.com/fda/ii/78240/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the USA
What quantity of product is in FDA event 78240?
The FDA record gives this quantity: 274 cartons
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2017 have the same class?
57% of the 343 drug events that started in 2017 are in Class II.